Synaffix licenses CliCr chemistry from Cristal Therapeutics

Truly emboldened by the signed license agreement with Synaffix as it underscores the potential of our unique CliCr® technology! This represents an important milestone in the execution of our strategy to commercialize CliCr® in different fields of diagnostic and therapeutic bioconjugates. Please contact us in case of any interest! Synaffix license CliCr Cristal Therapeutics

New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging

Maastricht, The Netherlands, 4 May 2022 – Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the publication of the results of the clinical PICCOLO study in the peer-reviewed journal, Advanced Materials1. This first-of-its-kind study2, part funded by an EU Horizon […]

BIO Digital

June 14-17 2021 BIO Digital Digital

BIO Europe Spring

March 22-25 2021 BIO Europe Spring Digital

LSX World Congress

February 01-05 2021 LSX World Congress Digital

Biotech Showcase

January 11-13 2021 Biotech Showcase Digital

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a […]

BIO Europe

October 26-29 2020 BIO-Europe Digital

Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties

Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development CliCr® can be partnered or licensed as a stand-alone technology Cristal is actively seeking partners for CliCr® for a variety of applications Maastricht, The Netherlands, 29 September 2020 – Cristal Therapeutics, […]

Oncology Virtual Partnering

September 22-24 2020 Oncology Virtual Partnering Digital